Coombs Test: Indications and Interpretation
Direct Answer
The direct antiglobulin test (DAT/Coombs) should be performed on cord blood of all newborns when the mother is Rh-negative or has not had prenatal blood typing, and is optional but not required for group O Rh-positive mothers if appropriate surveillance is in place 1.
Indications for Testing
Neonatal Context (Primary Indication)
Prenatal screening:
- All pregnant women require ABO and Rh(D) blood typing with serum screening for unusual isoimmune antibodies 1
Cord blood testing (Direct Coombs/DAT):
- Mandatory when mother is Rh-negative or lacks prenatal blood grouping - perform DAT, blood type, and Rh(D) typing on infant's cord blood 1
- Optional when maternal blood is group O, Rh-positive, provided adequate surveillance and follow-up exist 1
Clinical significance: DAT-positive infants have significantly higher phototherapy needs (51.5% vs 16.6% in DAT-negative infants), and when combined with positive maternal indirect antiglobulin test (IAT), the clinical course is substantially more severe with higher rates of severe hemolytic disease, elevated bilirubin, longer phototherapy duration, and increased IVIG use 2.
Beyond Neonatal Period
The DAT is indicated when evaluating hemolysis to distinguish immune from non-immune etiologies, including:
- Autoimmune hemolytic anemia
- Transfusion-related hemolysis
- Drug-induced hemolytic anemia
- Passenger lymphocyte syndrome 3
Test Interpretation
Direct Antiglobulin Test (DAT)
What it detects: IgG, complement (C3), or both bound to red blood cell membranes 4, 5
Positive DAT in newborns indicates:
- ABO incompatibility (45.9% of DAT-positive cases)
- RhD incompatibility (5.7%)
- Combined RhD and ABO incompatibility (10.3%)
- Subgroup incompatibility or other RBC antibodies (18.3%) 2
Indirect Antiglobulin Test (IAT)
What it detects: Antibodies present in maternal serum/plasma (not bound to RBCs) 2
Critical finding: When mothers of DAT-positive babies are also IAT-positive, expect significantly worse clinical outcomes - this combination predicts severe hemolytic disease requiring more aggressive intervention 2.
Key Clinical Algorithm
- All pregnant women → ABO/Rh typing + antibody screen (IAT)
- If mother Rh-negative or no prenatal typing → Cord blood DAT + infant blood type/Rh mandatory
- If mother group O, Rh-positive → Cord blood DAT optional (but ensure close monitoring)
- If infant DAT-positive → Check maternal IAT if not done prenatally
- If both DAT-positive AND maternal IAT-positive → Anticipate severe disease requiring intensive phototherapy, possible IVIG, closer monitoring
Critical Pitfalls and Caveats
False-negative DAT results occur in:
- IgG sensitization below detection threshold of commercial reagents
- Low-affinity IgG antibodies removed during standard washing procedures
- IgA-only or monomeric IgM-only sensitization without complement fixation (commercial reagents typically only detect IgG and C3) 6
False-positive results from:
- Improper washing, centrifugation, or specimen handling
- Spontaneous RBC agglutination 3
Important limitation: The IAT has high specificity (96-100%) but lower sensitivity (9-57% depending on technique) compared to DAT, meaning negative IAT does not rule out immune-mediated disease when DAT is positive 7.
Do not rely on visual jaundice assessment alone - it leads to errors in estimating bilirubin levels. Use transcutaneous bilirubin measurement or serum testing 1.